Abstract Synergy study with chemotherapeutic agents is a common in vitro strategy in the search for effective cancer therapy. For non-chemotherapeutic agents, efficacious synergistic effects are uncommon. Here, we have examined two non-chemotherapeutic agents for synergistic effects: lovastatin and Tumor Necrosis Factor (TNF)-related apoptosis-inducing ligand (TRAIL) for synergistic effects; on three human malignant glioblastoma cell lines, M059K, M59J, and A172. Cells treated with lovastatin plus TRAIL for 48 h showed 50% apoptotic cell death, whereas TRAIL alone (1,000 ng/ml) did not, suggesting that lovastatin sensitized the glioblastoma cells to TRAIL attack. Cell cycle analysis indicated that lovastatin increased G 0 -G 1 arrest in these cells. Annexin V study demonstrated that apoptosis was the predominant mode of cell death. We conclude that the combination of lovastatin and TRAIL enhances apoptosis synergistically. Moreover, lovastatin sensitized glioblastoma cells to TRAIL, suggesting a new strategy to treat glioblastoma.
Introduction
Glioblastomas are the most common intracranial brain tumors. Its prognosis is usually poor, with survival times of less than 15 months from first diagnosis [1] . Surgical resection and chemotherapy are common treatments [2] . Despite recent advances in the understanding of the molecular mechanism of tumourogenesis, the outcome of malignant glioma remains poor [3] . Thus, new effective forms of therapy are needed.
The Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) [4] , a member of the TNF superfamily, can bind with death receptors, DR4 and DR5 [5, 6] and induces apoptosis in a wide range of cancer cells without harming normal cells. The specific property of TRAIL has attracted many researchers to look for new treatments by combining it with chemotherapeutic agents such as phenoxazine derivatives [7] , doxorubicin and cisplatin [8] . Such combinations have shown synergistic effects on different types of cancer cells in vitro.
Lovastatin, a 3-hydroxy-3-methlyglutaryl CoA (HMG CoA) reductase inhibitor is a commonly used cholesterollowering agent for prevention of atherosclerotic cardiovascular diseases [9, 10] . Lovastatin blocks the mevalonate pathway and reduces the formation of the downstream products, cholesterol, geranylgeranyl proteins, farnesylated [11] . Recently both in vitro and in vitro studies have found that lovastatin has antiproliferative, proapoptotic and antiinvasive properties in a wide range of cancer cell types [12] . Lovastatin is known to have an apoptotic effect on tumor cells and its combination with chemotherapeutics and cytokines often exert a synergistic effect against tumor growth [13] [14] [15] . The mechanism that leads to lovastatininduced apoptosis is not yet clear but the main event is thought to be associated with the alteration of mitochondrial stress, which releases cytochrome C, activates procaspase cascade and finally leads to apoptotic cell death.
Escape from apoptotic regulation is one of the major characteristics of cancer [16, 17] , and many successful anti-cancer agents induce apoptosis by damaging DNA. Unfortunately such agents may also severely affect normal cells. Given the fact that both lovastatin and TRAIL are non-chemotherapeutic agents and capable of inducing apoptosis in different types of cancer cells, it is important to determine whether the combination of these two agents would produce synergistic effects that may be lighten for a novel therapeutic application in gliomas.
We therefore hypothesized that the combination of TRAIL and lovastatin, neither of which alone has noxious effects on healthy cells, could generate a regime that was effective in killing cancer cells but caused minimal insult to normal healthy cells. In this study we report the effects of TRAIL in combination with a non-chemotherapeutic drug, lovastatin, on glioblastoma cells.
Materials and methods

Reagents
2-Methyl-1,2,3,7,8,8a-hexahdro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1-naphthalenyl ester butanoic acid (Lovastatin), DL-Mevalonic acid lactone, and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were purchased from Sigma (St Louis, MO). Lovastatin was dissolved in DMSO for stock and adjusted to final concentrations using complete medium or serum free medium. Soluble Human TRAIL (Apo2L) was affinity purified from lysates of bacteria transformed with pET plasmid containing TRAIL [18] . Cellular DNA fragmentation ELISA kit (Roche, Mannheim, Germany), RNeasy kit, DNA extraction kit (Qiagen, Germany) and RT-PCR kit (Promega, Madison, WI) were used. Three primary antibodies used were as follows: rabbit polyclonal antibody to DR4 (Chemicon International, 1:1,000 dilution), rabbit polyclonal antibody to DR5 (Cell Signaling Technology, 1:1,000 dilution), and rabbit polyclonal antibody to b-tubulin (Santa Cruz Biotechnology, 1:1,000 dilution). Goat anti-rabbit secondary antibody was obtained from Santa Cruz Biotechnology.
Cell culture
Three human glioblastoma cell lines, A172, M059J, and M059K were purchased from American Type Culture Collection (Rockville, MD). The glioblastoma cells were kept in Dulbecco's modified Eagle's medium (DMEM/ F12) (GIBCO BRL, Grand Island, NY) with or without 10% fetal bovine serum, 1% penicillin and streptomycin at 37°C under 5% CO 2 . Media were changed every 3 days.
Measurement of cell viability
We measured cell viability using the MTT assay. MTT is a water-soluble tetrazolium salt that is metabolized by viable cells to a colored, water-insoluble formazan salt. Thus the salt allows cell viability measurements. In short, 1 · 10 4 cells were cultured in the serum free DMEM/F12 medium in the presence of lovastatin with or without TRAIL in a 96 well microtiter plate for designated time periods. The medium was aspirated and 100 ll MTT (0.5 mg/ml in PBS) were added to each well and the cells incubated for 3 h. After MTT medium was aspirated, the cells were solubilized in 200 ll DMSO. The optical density of each sample at 570 nm (reference 630 nm) was measured using a microplate reader. The optical density of the media was proportional to the degree of viable cells.
Cell cycle analysis
Propidium iodide (PI) staining and flow cytometry were used to determine the stage of the cell cycle. Cells were treated with 20 lM lovastatin for 48 h at 37°C and the control cells were treated with normal medium (DMSO) or serum free medium (DMSO). 2 · 10 6 treated cells were washed with 5 ml PBS and then were trypsinized at 37°C for 5-10 min. Cells were spun down and washed with 5 ml PBS. Finally cells were resuspended in 500 ll PBS and fixed with 4.5 ml 70% Ethanol with gentle vortexing. Cells were allowed to sit in -20°C for overnight. Fixed cells were spun down and washed with 5 ml PBS, and then cells were resuspended in 500 ll PI (2 lg/ ml)/Triton X-100 (0.1% v/v) staining solution with RNase A (200 lg/ml) in dark and analyzed by a flow cytometer. The staining solution was purchased from Chemicon (Temecula, CA).
Apoptosis assay
Apoptotic cells were determined by two methods, Annexin-V and PI stained cells by flow cytometry and DNA fragmentation assay. During apoptosis, translocation of phosphatidylserine from inner membrane to outer membrane is a common phenomenon. Cells were stained with Annexin V for analysis of phosphoserine inversion, which was considered to be a sensitive marker of apoptosis. Using an Annexin V-FITC apoptosis detection kit (Molecular Probe Inc, Eugene, OR), the levels of binding of Annexin V and staining with PI were measured for the detection of early and late apoptosis respectively. All of the procedures were preformed under manufacturer's guidelines. Cells were treated with lovastatin or/and TRAIL for 48 h and then stained with Annexin-V and PI. Viable cells were recognized as negative for both Annexin-V and PI; early apoptotic events were positive for Annexin-V but negative for PI staining. Late apoptotic events were positive to both Annexin V and PI. Necrotic cells were positive for PI staining only.
DNA fragmentation determination, was carried out with the ELISA assay kit. After cells (1 · 10 4 ) were treated with lovastatin and/or TRAIL for 48 h, DNA fragmentation was detected using 96 wells microplate reader.
RT-PCR
Total RNA was isolated using Qiagen RNeasy extraction kit and performed according to the manufacturer's protocol. Total RNA (5 lg) was reversely transcribed using Promega RT-PCR kit and thermal program was set at 42°C for 15 min and 95°C for 5 min. PCR reaction was performed using the following primers, which have previously been tested successfully: TRAIL-R1, 
Western blot analysis
Western blot was performed according to previous description [19, 20] . Briefly, after 2 · 10 6 cells were treated for 48 h, total protein was isolated and reacted with the relevant antibodies. The probed proteins were visualized using the enhanced chemiluminescence Western blotting detection system (ECL Western Blotting Detection, Amersham Biosciences).
Statistics
The statistical significance was analyzed using one-way ANOVA analysis and Student's t-test. All statistical work was carried out using the SPSS software for Windows (Release 11.0.1, Chicago, IL). Differences were considered to be significant when P \ 0.05.
Results
Cell viability measured by MTT assay
We first examined the anti-proliferation effect of TRAIL on three glioblastoma cell lines. M059K and M059J glioblastoma cells were resistant to TRAIL-induced cell death and remained 100% cell viable following treatment in both normal and serum free conditions (Fig. 1a, b) . Only A172 showed minor cell death after TRAIL treatment (22%, Fig. 1a) .
Synergistic effects by TRAIL and lovastatin were then examined. A172, M059J, and M059K glioblastoma cells were incubated in 1, 5, 20, and 40 lM lovastatin alone or together with 500 ng/ml TRAIL for 48 h. In A172 glioblastoma cells, 5, 20, and 40 lM lovastatin with 500 ng/ ml TRAIL promoted significant cell death when compared with lovastatin control (Fig. 2a) . 5, 20 and 40 lM lovastatin alone induced 50%, 60% and 76% of cell death respectively, however in the presence of 500 ng/ml TRAIL, lovastatin induced 78%, 94%, and 92% of cell death respectively. 1, 5, 20, and 40 lM lovastatin with 500 ng/ml TRAIL also synergistically promoted cell death in M059J and M059K. In 40 lM lovastatin alone caused 40%, 55%, 40% and 60% cell death whereas in the presence of 500 ng/ml TRAIL, lovastatin induced 83%, 94%, 95% and 95% cell death respectively (Fig. 2b ). There were 26%, 51%, 58%, and 71% cell death induced by 1, 5, 20, and 40 lM lovastatin alone in M059K, in the presence of 500 ng/ml TRAIL, lovastatin at all concentration tested caused about 98% of cell death (Fig. 2c) . Collectively the combination of TRAIL and lovastatin was much more effective than lovastatin alone in the induction of cell death in all three glioblastoma cells tested and the result indicated that there was a synergistic effect when TRAIL and lovastatin were used together.
Cell cycle determination by PI staining Propidium iodide staining and flow cytometry were used to determine the degree of cell synchronization by 20 lM lovastatin. Cells were incubated with normal serum medium, serum free medium and 20 lM lovastatin with normal serum medium for 48 h. PI-stained cells were analyzed using flow cytometry to quantify cells in certain cell cycle stages. A significant increase in cell population at G0/G1 phase was observed when the cells were treated with 20 lM lovastatin indicating that lovastatin was able to arrest the cells at G0/G1 stage. G0/G1 cell population was also increased by serum free medium conditions (positive control) and the increase reached a significant level except in M059J cells (Fig. 3) .
Apoptosis is the major mode of cell death
In order to determine the mode of cell death induced by lovastatin and TRAIL, Annexin V and PI staining was employed for this purpose. Cells were incubated with 5 or 20 lM of lovastatin in the presence or absence of 500 ng/ ml TRAIL for 48 h. The percentage of cell death of glioblastoma cells treated with both lovastatin and TRAIL was significantly higher than that with either agent alone (Fig. 4a, b and c) . A172 glioblastoma cells were vulnerable to TRAIL induced apoptosis (Fig. 4a ) but significantly more apoptotic cells were observed following treatment with both TRAIL and lovastatin (P \ 0.005) (Fig. 4a) . TRAIL was able to induce apoptosis in 50% of A172 glioblastoma cells. However, TRAIL in combination with 5 and 20 lM could induce apoptosis in approximately 67% and 74% cells respectively, indicating a synergistic effect occurred. Similarly, a significant synergistic effect was also observed in M059K and M059J cells (P \ 0.005) (Fig. 4b, c) , with up to nearly a 10-fold increase in apoptotic cells. 5 lM lovastatin only induced apoptosis in 5.3% and 2.3% M059J and M059K respectively, which were not different from the control (without any treatment). 5 lM lovastatin plus 500 ng/ml TRAIL dramatically increased apoptotic cells to 47.8% and 61.4% in M059J and M059K respectively. M059J cells, which lack of DNA-dependent protein kinase expression [21] , were less vulnerable to the two agents, implying that DNA-dependent protein kinase may play a role in apoptosis induced by TRAIL and lovastatin. and 40 lM lovastatin alone or 0 lM lovastatin plus 500 ng/ml TRAIL, 5 lM lovastatin plus 500 ng/ml TRAIL, 20 lM lovastatin plus 500 ng/ml TRAIL and 40 lM lovastatin plus 500 ng/ml TRAIL for 48 h. Percentage of viable glioblastoma cells showed synergistic anti-proliferation effects by combined the two agents. In A172 glioblastoma cells (a), 500 ng/ml TRAIL with 5, 20 and 40 lM lovastatin induced cell death significantly when compared with lovastatin only groups. In M059J (b) and M059K (c), 500 ng/ml TRAIL with 1, 5, 20 and 40 lM lovastatin induced cell death significantly when compared with lovastatin only groups. ANOVA were used for statistics analysis and *P \ 0.05, **P \ 0.01. Experimental set were repeated for at least three times with triplicate wells for each condition (mean ± SD)
DNA fragmentation in glioblastoma cells
DNA fragmentation is one of the hallmarks when cells undergo apoptosis. We performed ELISA assay to confirm DNA fragmentation was induced in the cells treated with both lovastatin and TRAIL. A synergistic effect on DNA fragmentation by both agents was demonstrated in all three cell lines tested (Fig. 5a, b and c) . The level of DNA fragmentation was increased in treated A172 glioblastoma cells, but it was only statistically significant in the cells treated with TRAIL plus 20 lM lovastatin. In M059J and M059K cells, however, there was a dramatic elevation of DNA fragmentation in a dose-dependent manner when both of the agents were applied. This observation supports the argument that the cell death induced by the two agents was apoptotic and that both agents were able to function in a synergistic manner.
The expression of TRAIL receptors in glioblastoma cells
Resistance to cell death induced by TRAIL may be adapted by an altered level of TRAIL receptors. TRAIL-R3 (DcR1) and TRAIL-R4 (DcR2) are known to attenuate TRAILinduced apoptosis whereas TRAIL-R1 (DR4) and TRAIL-R2 (DR5) promote TRAIL-induced apoptosis [5] . The effect of lovastatin treatment on the TRAIL receptors was not determined. RT-PCR was performed to investigate the expression profiles on three glioblastoma cell lines tested. Cells were treated with normal serum medium, serum free medium, serum medium with 5 or 20 lM lovastatin for 48 h. TRAIL-R3 and R4 were not detected in all conditions and cell types tested. TRAIL-R1 was only detected on M059J cells with serum free medium or lovastatin (Fig. 6  a) . TRAIL-R2 was expressed on all cell types of cells with or without lovastatin and its level was not significantly different between lovastatin-treated cells and the controls. Therefore, the expression of TRAIL-R2 did not contribute to the lovastatin-induced cell death in glioblastoma cells tested. After we tested the mRNA expression of TRAIL receptors on glioblastoma cells, the further investigation was performed to determine the active protein expression of TRAIL-R1 and matured TRAIL-R2 by Western blot. The result showed that the protein expression profiles of TRAIL-R1 and TRAIL-R2 were found in three glioblastoma cells with or without lovastatin, suggesting the protein of these two receptors was underwent post-translational modifications. The significantly differences were only found on the TRAIL-R1 expression of M059K cells with 20 lM lovastatin (P = 0.05) and the expression of TRAIL-R2 in A172 cells with lovastatin (P \ 0.01) (Fig. 7) .
Discussion
Malignant glioblastoma is one of the major causes of brain tumors morbidity. Aggressive infiltration in the CNS ultimately leads to death in nearly all cases [2] . Malignant glioblastoma carries with aberrant biological and biochemical properties including several activating mutations that can lead to chemotherapeutics resistance [22] . Targeting apoptotic signaling machinery is thought to be a promising alternative for glioblastoma treatment [23] . The preliminary data presented in this report indicate that lovastatin, a blood cholesterol lowering medicine, sensitizes glioblastoma cells to TRAIL-mediated apoptosis. Earlier reports show statin-induced cell death through a mitochondrial-mediate pathway (intrinsic pathway) that is closely related to the Bcl-2 family protein Bid and activation of caspase 8, 9 and 3 [24] [25] [26] [27] . However, the mechanism for statin activation of caspase 8 remains unknown because caspase 8 is normally activated by receptor-mediated signals, such as Fas ligand and TRAIL [5] . Fig. 4 The synergistic apoptotic effects were quantified by flow cytometry using Annexin V and PI staining. Glioblastoma cells were treated with DMSO (Control), 5 lM lovastatin, 20 lM lovastatin, 500 ng/ml TRAIL, 5 lM lovastatin plus 500 ng/ml TRAIL and 20 lM lovastatin plus 500 ng/ml TRAIL for 48 h. Then cells were stained with Annexin V and PI to determine percentage of apoptotic cell death using flow cytometry. Synergistic apoptotic effects were observed in three glioblastoma cell lines A172 (a), M059J (b) and M059K (c), reached significant level. The portion of apoptotic cell death was indicated in lowright quarter of the flowcytometry scatter plot and the trend of apoptotic cells between groups. ANOVA were used for statistics analysis and *P \ 0.05, **P \ 0.01 (compared to control group), + P \ 0.05, ++ P \ 0.01 (compared to TRAIL only group). Experimental set were repeated for at least three times (mean ± SD) Lovastatin has been found to enhance TRAIL-induced cytotoxicity in a synergistic manner in glioblastoma cells. We demonstrated a synergistic effect produced by the combination of lovastatin and TRAIL on glioblastoma cells. Lovastatin was found to sensitize the cells to cell death induced by TRAIL. The mode of cell death induced by both agents in combination was apoptosis, as demonstrated by two different methods, Annexin V and PI staining and DNA fragmentation assay. We also demonstrated that two of the glioblastoma cell lines tested were resistant to TRAIL induced apoptosis. From this we inferred that lovastatin not only sensitized these glioblastoma cells through its effects on the TRAIL receptor pathway but also triggered an unknown mechanism: Lovastatin served as a cytostatic agent and turned on an unknown mechanism to support TRAIL-induced apoptosis in these glioblastoma cells. It has been shown that colon and lung tumor cells arrested in G 0 -G 1 stages are vulnerable to TRAIL-induced cell death [28] . However, our G 0 -G 1 arrested glioblastoma cell lines remained resistant to TRAIL-induced cell death in the serum free control. Our finding suggests that a combination of TRAIL and lovastatin together may form a new treatment for glioblastoma multiforme.
The mechanism by which lovastatin sensitizes glioblastoma cells to TRAIL induced-apoptosis remains unknown. In human glioblastoma, lovastatin has been shown to induce or to enhance apoptosis by altering a number of apoptotic molecules. For example, it can induce apoptosis or downregulate cell proliferation by targeting Ras in primary cultured human glioblastoma cells [29] and increase pro-apoptotic Bim in U87 and U251 glioblastoma cells [30] . Lovastatin has also been shown to downregulate RhoA and increase iNOS in T98G and A172 glioblastoma cells [31] . Additionally, Lovastatin may induce apoptosis by increasing p21 and the apoptosis induced can be prevented by the overexpression of Bcl-2 [32] , suggesting a mitochondrial-related apoptosis. It is noted that this study by Schmidt et al. fails to document that lovastatin can enhance death receptor (CD95)-mediated apoptosis in glioblastoma cells LN-18, LN-229, LN-308 and T98G [32] . The result from our study indicate that lovastatin in combination with TRAIL can synergistically induce apoptosis in A172, M059K and M059J glioblastoma cells. The apoptosis induced is associated with G 0 -G 1 arrest but not with pro-apoptotic Bid (data not shown). It is well known that TRAIL-induced apoptosis takes place via a death receptor-mediated pathway [5, 33] .
Our study showed that TRAIL-R1 mRNA expressed in M059J but was hardly detected in the other two cell lines. However, TRAIL-R1 protein was detectable in all three cell lines, suggesting that the TRAIL-R1 was modified by a post-translational mechanism in the cells tested. The level of TRAIL-R1 protein was higher in M059K cells treated with 20 lM of lovastatin. However, such an elevation of TRAIL-R1 is unlikely to be responsible for apoptosis induced by lovastatin because the apoptotic rate between M059K was not different from the other cell lines. TRAIL-R2 can be detected at both protein and RNA levels. The level of TRAIL-2 mRNA was not different in the cells treated with lovastatin but its protein level was much higher in A178 cells treated with either 5 or 10 mM lovastatin, the result of which indicated that TRAIL-R2 was modified by a post-translational mechanism in A172 cells. It is noted that the base level of TRAIL-2 in A172 cells does not differ from other two cell lines tested. Therefore, it is unlikely that TRAIL-2 could count for the relatively higher sensitivity of A172 cells to TRAIL stimulation than the other two cell lines. All three cell lines underwent a similar level of cell death when they were treated by lovastatin. Therefore, the contribution of lovastatin-induced TRAIL-2 protein to the cell death in A172 cells seems to be minimal. Such results appear to be in line with a study using mevastatin, a similar HMG-CoA reductase inhibitor. Mevastatin can significantly induce apoptosis of myeloma cells in a pathway independent of death receptors including Fig. 6 The expression of TRAIL receptor mRNA in glioblastoma cells. The cells were treated with normal serum medium, serum free medium, 5 and 20 lM lovastatin with normal serum medium. At the end of the treatment, RNA was isolated for the detection of TRAIL-R1 (DR4) (a) and TRAIL-R2 (DR5) (b) by RT-PCR TRAIL-R2 [34] . Nevertheless, further quantitative tests are needed in glioblastoma cells to verify the result obtained.
Apoptosis induced by lovastatin is generally considered to be via the mitochondrial-mediated pathway [30; 32] . It is possible for both pathways to talk to each other to amplify apoptotic signals and this is indeed a case for TRAIL, since TRAIL is capable of inducing either mitochondrial-independent or -dependent apoptotic pathways in some types of cells [17, 33] . The Bid is a molecule functions as a bridge that links death receptor-and mitochondrial-mediated pathways. Therefore, without involvement of Bid, apoptosis induced by TRAIL and lovastatin in combination in the present study seem to be separately mediated by these two pathways. However, considering the fact that two out of three glioblastoma cells tested are insensitive to TRAIL treatment but they become responsive in the presence of lovastatin, it can be hypothesized that lovastatin treatment may remove an unknown inhibitory factor(s) that overcomes the TRAIL-mediated pathway or that lovastatin may ''wake up'' an activator(s) that normally remains in a resting condition. One of inhibitory factors known to involve TRAIL-mediated pathways is its decoys, TRAIL-R3 and TRAIL-R4 [5, 33] . However, it can be seem from our study that this inhibitory factor(s), if any, should not be the decoys TRAIL-R3 and TRAIL-R4 since both are not detectable in the cells tested. One possible explanation for this synergistic effect is the activation of caspase 8, an initiator caspase in death receptor-mediated pathways. Lovastatin has been shown to enhance caspase 8 activity [35] . It is possible that caspase-8 is the activator factors waken up by lovastatin. Whatever it is, the mechanism accounting for the synergistic effect of TRAIL and lovastatin against glioblastoma cells in the present study is complicated and remains to be uncovered.
Mevalonate is a critical component of a complex biochemical pathway and its products are vital for a variety of important cellular functions including cell signaling, protein synthesis, and cell cycle regulation [11] . Little is known about the molecular events leading to apoptosis of cancer cells due to lovastatin exposure. It is likely that apoptosis is abrogated by mevalonate and GGPP and is partially reversed by FPP [12] .
Our results also reinforced the conclusion of our previous study, that DNA-dependent protein kinase (DNA-PK) plays an important role in cell apoptosis. M059J cells that lack of DNA-PK activity are resistant not only to total cell death but also apoptosis [19, 20] . Experts disagree over the functions of DNA-PK in cell regulation. DNA-PK has been reported to promote cell death by interacting with telomeres, whereas other reports suggest that DNA-PK protects cells from cell death via caspase-independent or p53 independent pathways. The reason for this paradoxical finding remains unknown.
This study demonstrated a synergistic interaction between lovastatin and TRAIL, but the mechanisms of action by which lovastatin sensitized glioblastoma cells remains unknown. Our results are in agreement with the concept of combined cancer therapeutic action via both intrinsic and extrinsic apoptotic cell death pathways. This combination of non-chemotherapeutic agents, TRAIL and lovastatin, may offer a potential regime for glioblastoma treatment.
